title: Successful treatment with S-1 plus CPT-11 for lymph node metastasis from colon cancer: report of a case.
abstract: S-1 is a novel oral anticancer drug, composed of tegafur (FT), gimestat (CDHP) and otastat potassium (Oxo), based on the biochemical modulation of 5-fluorouracil (5-FU). S-1 plus irinotecan (CPT-11) for advanced colorectal cancer as expected showed equally good results as these with CPT-11 plus infusional 5-FU/LV (FOLFIRI regimen). A case of unresectable lymph node metastasis from colon cancer successfully treated with S-1 plus CPT-11 is reported here. A 65-year-old man had metastasis to the lymph nodes in the left supra clavicular region and the superior mesenteric artery. S-1 plus CPT-11 was chosen for the treatment. After 2 courses, since grade 2 toxicity for dysgeusia was observed, S-1 administration was shortened. After 3 courses of the revised regimen, the enlarged lymph nodes disappeared on conventional CT and fluorine-18 fluorodeoxyglucose positron emission tomography with CT (FDG-PET/CT) and the case was assessed as a complete response (CR). Because CR was continued by an additional four courses of treatment, the regimen was changed to a single administration of S-1. Although eighteen months have passed since the induction of CR by S-1 plus CPT-11 therapy, no symptoms or findings of relapse have been observed.
authors.affiliation: Department of Surgery, Tokyo Women's Medical University Medical Center East, 2-1-10 Nishiogu Arakawa-ku, Tokyo 116-8567, Japan. kyoshsu@dnh.twmu.ac.jp
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Yoshimatsu
authors.forename: Hajime
authors.initials: H
authors.lastname: Yokomizo
authors.forename: Takashi
authors.initials: T
authors.lastname: Fujimoto
authors.forename: Taisuke
authors.initials: T
authors.lastname: Otani
authors.forename: Atsuo
authors.initials: A
authors.lastname: Matsumoto
authors.forename: Gakuji
authors.initials: G
authors.lastname: Osawa
authors.forename: Hiroko
authors.initials: H
authors.lastname: Itagaki
authors.forename: Arihiri
authors.initials: A
authors.lastname: Umehara
authors.forename: Shunichi
authors.initials: S
authors.lastname: Shiozawa
authors.forename: Takao
authors.initials: T
authors.lastname: Katsube
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Naritaka
authors.forename: Kenji
authors.initials: K
authors.lastname: Ogawa
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004338:Drug Combinations; D006801:Humans; D000077146:Irinotecan; D008207:Lymphatic Metastasis; D008297:Male; D010094:Oxonic Acid / Q000008:administration & dosage; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000077146:Irinotecan; D002166:Camptothecin